Olmesartan Medoxomil/Hydrochloorthiazide Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan Medoxil/Hydrochlorothiazide is indicated for hypertension management, acting on the renin‑angiotensin‑aldosterone system and fluid balance.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Hypertension with fluid retention: provides additional blood‑pressure reduction through diuretic action.
• Hypertension in patients who require an angiotensin receptor blocker combined with a thiazide diuretic: offers convenient dual therapy in a single tablet.

• Olmesartan medoxil selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth‑muscle and adrenal cells, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis, which together lower systemic vascular resistance and blood volume.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Cough
• Increased urination
• Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Liver function abnormalities
• Severe skin reactions such as Stevens‑Johnson syndrome

Before starting therapy, clinicians should assess patient history and monitor relevant parameters.

• Renal function: evaluate baseline creatinine and eGFR.
• Electrolytes: check serum potassium and sodium levels.
• Pregnancy: avoid use; drug is contraindicated in the second and third trimesters.
• Concomitant NSAIDs: may reduce antihypertensive effect and increase renal risk.
• Gout: monitor uric acid as thiazides can precipitate attacks.

Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil/Hydrochlorothiazide may interact with several drug classes; monitoring and dosage adjustments are often required.

Major Interactions (Avoid)

• Aliskiren: combined use can cause excessive potassium elevation and renal impairment.
• Potassium‑saving diuretics or supplements: risk of hyper‑kalemia.
• Lithium: increased lithium levels may lead to toxicity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive response and affect renal function.
• ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, risk of hypotension.
• Antidiabetic drugs: may enhance hypoglycaemic effect.
• CYP450 inhibitors: may modestly increase olmesartan concentrations.